CNTF and macular telangiectasia type 2: <h4>Objective</h4>To primarily assess long-term safety and retinal imaging outcomes of NT-501 (revakinagene taroretcel-lwey), which releases ciliary neurotrophic factor into the vitreous over an extended time, for treating macular telangiectasia type 2 (MacTel).<h4>Design</h4>Phase I, nonrandomized, multicenter, open-label extension study.<h4>Participants</h4>Six participants with bilateral MacTel who completed the parent 60-month phase I study.<h4>Methods</h4>In the parent study, participants had NT-501 surgically implanted in the study eye.